ABT-263

DRUG18 trials

Sponsors

AbbVie (prior sponsor, Abbott), AbbVie, Abbott, Genentech, Inc., Rutgers, The State University of New Jersey

Conditions

B-cell Chronic Lymphocytic LeukemiaCD20-Positive Lymphoid MalignanciesChronic Lymphocytic LeukemiaChronic Lymphoid LeukemiaFollicular LymphomaHealthy Female SubjectsHematological MalignanciesLeukemias

Phase 1

A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies

CompletedNCT00406809

AbbVie (prior sponsor, Abbott)Chronic Lymphoid Leukemia, Follicular Lymphoma, Lymphoid Malignancies +3

Start: 2006-11-30End: 2016-10-31Updated: 2021-08-02

A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies

CompletedNCT00445198

AbbVie (prior sponsor, Abbott)Small Cell Lung Cancer, Small Cell Lung Carcinoma

Start: 2007-04-30End: 2010-12-31Updated: 2018-06-06

A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

CompletedNCT00481091

AbbVieChronic Lymphocytic Leukemia

Start: 2007-07-25End: 2022-05-12Updated: 2023-06-13

Assess the Oral Bioavailability of New ABT-263 Formulations

CompletedNCT00743028

AbbottChronic Lymphocytic Leukemia, Leukemias, Lymphomas

Start: 2008-08-31Updated: 2010-10-07

Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers

CompletedNCT00788684

AbbVieCD20-Positive Lymphoid Malignancies, Chronic Lymphoid Leukemia, Hematological Malignancies +1

Start: 2009-07-21End: 2025-02-07Updated: 2025-02-20

Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

CompletedNCT00868413

AbbVie (prior sponsor, Abbott)Chronic Lymphocytic Leukemia

Start: 2009-11-30End: 2013-05-31Updated: 2013-06-07

A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer

CompletedNCT00878449

AbbVie (prior sponsor, Abbott)Solid Tumors

Start: 2009-10-31End: 2011-07-31Updated: 2018-06-06

Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors

CompletedNCT00887757

AbbVieSolid Tumors

Start: 2009-09-30End: 2011-11-30Updated: 2017-11-21

Safety Profile, MTD, and PK Profile Studies of ABT-263 When Administered in Combination With Standard and Weekly Regimens of Docetaxel in Subjects With Cancer

CompletedNCT00888108

AbbottSolid Tumor

Start: 2009-07-31End: 2012-03-31Updated: 2012-05-22

Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors

CompletedNCT00891605

AbbVieSolid Tumors

Start: 2009-07-31End: 2012-07-31Updated: 2017-11-21

Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With Cancer

CompletedNCT00982566

AbbVieLymphoid Malignancy, Solid Tumors

Start: 2009-10-31End: 2010-12-31Updated: 2017-11-21

A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects

CompletedNCT01009073

AbbVie (prior sponsor, Abbott)Solid Tumors

Start: 2009-10-31End: 2013-06-30Updated: 2017-11-20

A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).

CompletedNCT01021358

AbbottChronic Lymphocytic Leukemia, Lymphoma, Solid Tumors

Start: 2010-01-31Target: 12Updated: 2010-12-20

Assess the Oral Bioavailability of a New ABT-263 Formulation in Healthy Female Subjects

CompletedNCT01053520

AbbottHealthy Female Subjects

Start: 2009-10-31End: 2010-01-31Target: 12Updated: 2010-11-09

Phase 2

Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic Lymphocytic Leukemia (CLL) Who Have Failed at Least One Prior Fludarabine-containing Regimen

WithdrawnNCT00918450

AbbottB-cell Chronic Lymphocytic Leukemia

Start: 2010-03-31Target: 150Updated: 2010-02-26

A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)

CompletedNCT01087151

Genentech, Inc.Chronic Lymphocytic Leukemia

Start: 2010-08-31End: 2012-06-30Updated: 2016-11-02

Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer

TerminatedNCT01828476

Rutgers, The State University of New JerseyProstate Cancer

Start: 2013-06-30End: 2016-03-03Updated: 2017-05-04

A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer

CompletedNCT02591095

Centre Francois BaclessePlatinum-resistant or Refractory Ovarian Cancer

Start: 2016-01-31End: 2019-03-31Updated: 2019-03-19

Related Papers

A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO study.

2022-02-0219 citations

A Phase I Study of the Safety, Pharmacokinetics and Efficacy of Navitoclax Plus Docetaxel in Patients with Advanced Solid Tumors

Future Oncology2021-04-1428 citations

Safety and efficacy of navitoclax, a BCL-2 and BCL-X <sub>L</sub> inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study

Leukemia & lymphoma/Leukemia and lymphoma2020-11-2581 citations

Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors.

2015-09-2950 citations

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.

2010-11-18672 citations